Clinical trials: Bioavailability Study
Bioavailability
Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.
- Trial name
- NCT02557139
- Testing
- Belumosudil Tablet, Belumosudil Capsule
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Kadmon Corporation, LLC
Healthy
PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers
The current study is being conducted to evaluate the relative bioavailability and single- and multiple-dose pharmacokinetics of encapsulated mesalamine granules(eMG) in healthy subjects.
- Trial name
- NCT00622375
- Testing
- mesalamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Autoimmune Diseases
A SHR0302 BA Study on Healthy Subjects
The purpose of this study is to evaluate and compare the pharmacokinetics of SHR0302 two different kind tablets in Healthy subjects after administration two kind tablets (quick release tablets and sustained-release tablets).
- Trial name
- NCT06202612
- Testing
- SHR0302 quick release tablets, SHR0302 sustained-release tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Allergic Rhino-Conjunctivitis, Urticaria
To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions
An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT07042828
- Testing
- Bilastine oral dispersible tablets, Bilaxten oral dispersible tablets
- Where
- India
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Parkinson Disease
Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
The purpose of this study is to evaluate the bioavailability and the bioequivalence between two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage strengths (25 mg and 50 mg) after a single…
- Trial name
- NCT03116295
- Testing
- Opicapone (OPC)
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers
Study to compare the bioavailable fraction of epinastine and pseudoephedrine when administered as a fixed dose combination in tablet form (new pharmaceutical formulation), with that obtained with each of these drugs when…
- Trial name
- NCT02182531
- Testing
- Epinastine, Pseudoephedrine, Epinastine + Pseudoephedrine combination
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
ECC5004 RBA FE Study in Healthy Participants
This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet…
- Trial name
- NCT06268145
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eccogene
Healthy
A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study conducted at a single study center to characterize the relative bioavailability of relacorilant administered as 3×100-mg softgel capsules…
- Trial name
- NCT03540836
- Testing
- Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy
Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions
To compare the single-dose oral bioavailability of metformin HCI liquid 500 mg/5 mL of Ranbaxy with Glucophage® 1000 mg tablets of Bristol-Myers, USA following administration of a 1000 mg dose in healthy, adult, male and female…
- Trial name
- NCT00778765
- Testing
- 400 mg Gabapentin Capsules
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Healthy
The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation
The current study will investigate the relative bioavailability of a spray dried dispersion solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF 06260414 relative to a single oral dose of 30 mg…
- Trial name
- NCT02393807
- Testing
- PF 06260414 solid dose formulation, PF-06260414 nanosuspension
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers
Study to investigate the relative bioavailability of 5 mg BI 1356 as tablet formulations (Trial formulation) TF II and Intended final formulation (iFF) vs. 5 mg BI 1356 as tablet TF IIb
- Trial name
- NCT02183363
- Testing
- BI 1356 - Tablet TFII, BI 1356 - Tablet iFF, BI 1356 - Tablet TFIIb
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bioequivalence
Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product
This Pilot study will investigate the bioavailability in fasting women of 2 tablet formulations containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The Pilot study will be performed at a single site with 30 subjects.
- Trial name
- NCT04194905
- Testing
- Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product, Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product
- Where
- Chile
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Laboratorios Andromaco S.A.
Healthy
Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
The objective of this study is to assess the bioavailability of the MGCD265 formulation following oral administration under fed conditions (Treatment-1) as compared to fasting conditions (Treatment-2) in healthy male and female…
- Trial name
- NCT02117245
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Coenzyme Q10, Oxidative Stress
Bioavailability and Impact of Coenzyme Q10 in Stressing Exercise in Senescence Athletes
It is proposed to establish a group of subjects composed of 10 healthy individuals of> 50 years and <65, physically active, without metabolic or inflammatory pathology.
- Conditions
- Coenzyme Q10, Oxidative Stress, Aging
- Trial name
- CoQ10Sport (NCT03893864)
- Testing
- Administration of a product with Fitosomed Ubiquinone, Coenzyme Q10 level in muscle biopsies, Coenzyme Q10 level in plasma, blood cells, urine cells
- Where
- Spain
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Centre d'Alt Rendiment
Healthy
A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions
The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg Extended-Release Tablet to that of Wellbutrin SR® 150 mg Tablet after a single, one-tablet dose in subjects fed a standard meal.
- Trial name
- NCT00865371
- Testing
- Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy Volunteer
Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets
The objective of this study is to assess bioequivalence of lumacaftor from Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) versus the reference commercial product, Lumacaftor 200 mg /Ivacaftor 125 mg Combination…
- Trial name
- NCT05968612
- Testing
- Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet, Lumacaftor 200 mg Film-Coated Tablet Formulation
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Qanatpharma Canada LTD
Healthy
Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects
This study is designed for descriptive pharmacokinetic characterization of ketamine and norketamine in serum, urine and feces after oral single dose administration of a new developed prolonged release tablet formulation…
- Trial name
- NCT02494830
- Testing
- Ketamine
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Healthy
Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.
The objective of this study is to compare the relative bioavailability of clarithromycin 500 mg tablets (Ranbaxy Laboratories Limited) with that of BIAXIN® 500 mg tablets in healthy, adult subjects under fasting conditions.
- Trial name
- NCT00774644
- Testing
- Clarithromycin 500mg
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Neuroblastoma
Oral Liquid 13-cis-retinoic Acid (13-CRA)
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.
- Trial name
- My-CRA (NCT03291080)
- Testing
- Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nova Laboratories Limited